Mark J. Casey
Net Worth
Last updated:
What is Mark J. Casey net worth?
The estimated net worth of Mr. Mark J. Casey is at least $21,907,521 as of 17 Dec 2020. He owns shares worth $640 as insider, has earned $6,881 from insider trading and has received compensation worth at least $21,900,000 in Mallinckrodt plc.
What is the salary of Mark J. Casey?
Mr. Mark J. Casey salary is $4,380,000 per year as Executive Vice President & Chief Legal Officer in Mallinckrodt plc.
How old is Mark J. Casey?
Mr. Mark J. Casey is 62 years old, born in 1963.
What stocks does Mark J. Casey currently own?
As insider, Mr. Mark J. Casey owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Mallinckrodt plc (MNKKQ) | Executive Vice President & Chief Legal Officer | 32,011 | $0.02 | $640 |
What does Mallinckrodt plc do?
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Mark J. Casey insider trading
Mallinckrodt plc
Mr. Mark J. Casey has made only one insider trade in 2020, according to the Form 4 filled with the SEC. He sold 15,291 units of MNKKQ stock worth $6,881 on 17 Dec 2020.
As of 17 Dec 2020 he still owns at least 32,011 units of MNKKQ stock.
Mallinckrodt key executives
Mallinckrodt plc executives and other stock owners filed with the SEC:
- Dr. Steven J. Romano M.D. (66) Executive Vice President & Chief Scientific Officer
- Mr. Bryan M. Reasons (58) Executive Vice President & Chief Financial Officer
- Mr. Hugh M. O'Neill (62) Executive Vice President & Chief Commercial and Operations Officer
- Mr. Mark Christopher Trudeau (64) Pres, Chief Executive Officer & Director
- Mr. Mark J. Casey (62) Executive Vice President & Chief Legal Officer